US 12,343,381 B2
Dosage regimen for pegylated interferon
Christoph Klade, Vienna (AT); Oleh Zagrijtschuk, Vienna (AT); and Ko-Chung Lin, Lexington, MA (US)
Assigned to PHARMAESSENTIA CORPORATION, Taipei (TW)
Filed by PharmaEssentia Corporation, Taipei (TW)
Filed on Dec. 23, 2022, as Appl. No. 18/088,272.
Application 18/088,272 is a continuation of application No. 15/518,423, granted, now 11,559,567, previously published as PCT/US2015/059410, filed on Nov. 6, 2015.
Claims priority of application No. 14192114 (EP), filed on Nov. 6, 2014.
Prior Publication US 2023/0131552 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/21 (2006.01); A61K 47/60 (2017.01); C07K 14/555 (2006.01); C07K 14/56 (2006.01)
CPC A61K 38/212 (2013.01) [A61K 38/21 (2013.01); A61K 47/60 (2017.08); C07K 14/555 (2013.01); C07K 14/56 (2013.01)] 22 Claims
 
1. A method of treating a myeloproliferative disease in a subject, wherein the myeloproliferative disease is polycythemia vera, the method comprising:
administering to a subject in need thereof a 50 to 540 μg dose of a pegylated type I interferon which has the following structure:

OG Complex Work Unit Chemistry
wherein the IFN is an interferon-α2b, and each of the mPEG has a molecular weight of 20 kD; and
wherein the pegylated type I interferon is administered at an interval of every 2 to 4 weeks for a treatment period, and wherein the treatment period is at least 16 months.